Short CV/Education and training

  • 1965 – 1969
    Bachelor of Arts (B. A.) in biology, Macalester College, St. Paul, MN, USA

  • 1970 – 1974
    Doctorate in genetics from the University of Wisconsin-Madison, USA

  • 1974 – 1975
    Postdoc at the National Institute of Health, University College London, England

  • 1976 – 1978
    Postdoc at the Sloan-Kettering Institute for Cancer Research, New York, New York, USA

  • 1978 – 1986
    Research associate at the Institute of Immunology, LMU Munich, Germany

  • 1984 – 1986
    Habilitation (postdoctoral qualification) in the field of immunology at LMU Munich

  • 1986 – 1996
    Professor (C2) of immunology at the Institute of Immunology, LMU Munich

  • 1996 – 1998
    Professor (C3) of immunology at the Institute of Immunology, LMU Munich

  • 1998
    - 2014 Director of the Institute of Molecular Immunology at the Helmholtz Centre in Munich

  • Since 1998
    Professor(emt.) of immunology at LMU Munich

  • Since 2013
    Chief executive officer of the Medigene Immunotherapies GmbH (previously Trianta Immunotherapies GmbH)

  • Since 2014
    Chief Scientific Officer of the Medigene AG

  • Since 2016
    Chief Executive Officer and Chief Scientific Officer of the Medigene AG

Selected publications

  • Leisegang, M. et al.: MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. In: J. Clin. Invest. 2010, in press.

  • Spranger, S. et al.: Generation of T helper-1 polarizing dendritic cells using the Toll-like receptor 7/8 agonist CL075. In: J. Immunol. 185(1), 2010. pp. 738-747.

  • Buchner, A. et al.: Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma. In: Hum. Gene Ther. 21(3), 2010. pp. 285-297.

  • Moosmann, A. et al.: Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. In: Blood 2009, in press.

  • Raffegerst, S.H. et al.: Diverse hematological malignancies including hodgkin-like lymphomas develop in chimeric MHC class II transgenic mice. In: PLoS One 4(12), 2009. e8539.

  • Brill, T.H. et al.: Therapeutic vaccination with an IL-2-IFNgamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer – a phase I/II trial. In: Hum. Gene Ther. 12, 2009. pp. 1641-1651.

  • Wilde, S. et al.: Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior anti-tumor activity and higher TCR functional avidity. In: Blood 114(10), 2009. pp. 2131-2139.

  • Zobywalski, A. et al.: Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. In: J. Transl. Med. 5(18), 2007 (highly accessed).

  • Endl, J. et al.: Coexpression of CD25 and OX40 (CD134) receptors delineates autoreactive T-cells in type 1 diabetes. In: Diabetes 55(1), 2006. pp. 50-60.

  • Engels, B. et al.: Redirecting human T lymphocytes towards renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. In: Hum. Gene Ther. 16(7), 2005. pp. 799-810.

  • Frankenberger, B. et al.: Influence of CD80, interleukin-2 and interleukin-7 expression in human renal cell carcinoma on the expansion, function and survival of tumor-specific CTLs. In: Clin. Cancer Res. 11(5), 2005. pp. 1733-1742.

  • Hartl, D. et al.: Pulmonary chemokines and their receptors differentiate children with asthma and chronic cough. In: J. Allergy and Clin. Immunol. 115(4), 2005. pp. 728-736.

Selected projects

  • Helmholtz Alliance – Immunotherapy of Cancer, "Immune Monitoring and Melanoma" project

  • Bay ImmuNet – Immunotherapy of High-Risk Acute Myeloid Leukaemia using Dendritic Cell Vaccination

  • Collaborative Research Centre (SFB) Transregio 36 – Bases and application of adoptive T-cell therapy

Membership in scientific bodies/juries

Membership in review boards:

  • Immunotherapy, since 2008

  • Journal of Translational Medicine, since 2004

  • Tissue Antigens, since 1991

  • Human Immunology, since 1984

Coordinator of science boards:

  • Member of the German Research Foundation (DFG) advisory board for clinical research, since 2009

  • Member of the executive committee, International Society of Biological Therapies (iSBTC), USA, since 2008

  • Member of the European Research Council, Brussels, life sciences section, since 2007

  • Transregio SFB 36, deputy spokesperson, since 2006

  • Member of the board of directors, Helmholtz Research Centre for Infectious Disease Biology, Braunschweig, Germany, since 2005

  • Member of the expert committee on clinical research, clinically oriented basic research for Deutsche Krebshilfe (German Cancer Aid), since 2004

  • Member of the DFG review board for microbiology, virology and immunology, since 2004

  • Acting chairperson of SFB 455, since 1999

  • Deputy chairperson of the science committee, Helmholtz Research Centre for Infectious Disease Biology, Braunschweig, since 1999

  • Advisor to the Wilhelm Vaillant Foundation, since 1999

Additional qualifications

  • Specialist in immunology


You can only see the contact information of the academics in the database if you are a registered user of AcademiaNet.
Please register here


  1. Read what our members say about AcademiaNet.

No more excuses!

  1. Please download the brochure "No more excuses" and read more about female experts in Europe, and about AcademiaNet.

Similar profiles

  1. Prof. Dr. Amparo Acker-Palmer

    Biological and related sciences , HealthCell Biology, Cellular and Molecular Neuroscience, Vascular Biology, Tumour Biology

  2. Dr. Chantal Abergel

    Biological and related sciences , Physical sciencesEnvironmental virology, Molecular and structural biology, biochemistry

  3. Dr. Malin Ah-King

    Biological and related sciences Evolutionary biology, Animal behaviour, Gender studies, Science studies

  4. Dr. Jessica Abbott

    Biological and related sciences Evolutionary biology, Evolutionary genetics



  1. Researchers Tweak Immune System to Target Tumor Cells

    Researchers at the Max Delbrück Center for Molecular Medicine MDC Berlin-Buch and the University Hospital Charité have succeeded in generating immune cells to specifically target and destroy cancer cells. Prof. Dolores Schendel of Medigene AG was part of the research team.